Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALGS NASDAQ:ASBP NASDAQ:ATHA NASDAQ:DARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$5.59+1.6%$5.84$4.80▼$13.69$34.60M2.25137,230 shs8,950 shsASBPAspire Biopharma$6.36-1.4%$6.18$3.31▼$1,050.36$8.27M0.17431,812 shs16,437 shsATHAAthira Pharma$8.22-4.5%$9.15$0.23▼$8.36$32.42M2.79602,475 shs15,987 shsDAREDare Bioscience$2.04+2.0%$2.30$1.27▼$9.19$30.56M1.07364,482 shs8,768 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics-1.26%+4.17%-4.18%-17.42%-27.92%ASBPAspire Biopharma-1.38%-1.98%+27.22%-76.46%-97.76%ATHAAthira Pharma0.00%0.00%-20.43%-15.08%+163.46%DAREDare Bioscience-3.85%-7.83%-14.53%+29.03%-24.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$5.59+1.6%$5.84$4.80▼$13.69$34.60M2.25137,230 shs8,950 shsASBPAspire Biopharma$6.36-1.4%$6.18$3.31▼$1,050.36$8.27M0.17431,812 shs16,437 shsATHAAthira Pharma$8.22-4.5%$9.15$0.23▼$8.36$32.42M2.79602,475 shs15,987 shsDAREDare Bioscience$2.04+2.0%$2.30$1.27▼$9.19$30.56M1.07364,482 shs8,768 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics-1.26%+4.17%-4.18%-17.42%-27.92%ASBPAspire Biopharma-1.38%-1.98%+27.22%-76.46%-97.76%ATHAAthira Pharma0.00%0.00%-20.43%-15.08%+163.46%DAREDare Bioscience-3.85%-7.83%-14.53%+29.03%-24.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALGSAligos Therapeutics 2.86Moderate Buy$38.50588.73% UpsideASBPAspire Biopharma 1.00SellN/AN/AATHAAthira Pharma 1.00Sell$4.00-51.34% DownsideDAREDare Bioscience 2.33Hold$10.00390.20% UpsideCurrent Analyst Ratings BreakdownLatest ASBP, ALGS, DARE, and ATHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026ALGSAligos Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/28/2026ALGSAligos Therapeutics Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.005/21/2026ALGSAligos Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.005/21/2026ALGSAligos Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.004/20/2026ALGSAligos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ASBPAspire Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026DAREDare Bioscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/26/2026ALGSAligos Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/26/2026ALGSAligos Therapeutics Westpark CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$48.00(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALGSAligos Therapeutics$2.19M15.80N/AN/A$8.67 per share0.64ASBPAspire Biopharma$10K826.80N/AN/A($54.19) per share-0.12ATHAAthira PharmaN/AN/AN/AN/A$11.60 per shareN/ADAREDare Bioscience$1.16M26.41N/AN/A$0.20 per share10.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALGSAligos Therapeutics-$24.19M-$8.69N/AN/AN/A-1,919.68%-139.47%-90.88%8/5/2026 (Estimated)ASBPAspire Biopharma-$24.48M-$116.67N/AN/AN/AN/AN/A-398.04%N/AATHAAthira Pharma-$96.94M-$9.68N/AN/AN/AN/A-107.06%-89.89%N/ADAREDare Bioscience-$13.40M-$0.95N/AN/AN/AN/AN/A-46.22%8/13/2026 (Estimated)Latest ASBP, ALGS, DARE, and ATHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026ASBPAspire BiopharmaN/A-$20.57N/A-$20.57N/A$0.03 million5/14/2026Q1 2026DAREDare Bioscience-$0.33-$0.20+$0.13-$0.21$0.03 million$0.15 million5/7/2026Q1 2026ALGSAligos Therapeutics-$2.29-$2.21+$0.08-$2.21$0.25 million$2.83 million3/30/2026Q4 2025ASBPAspire BiopharmaN/A-$1.65N/A-$478.50N/A$0.00 million3/26/2026Q4 2025DAREDare Bioscience-$0.44-$0.02+$0.42-$0.02$0.75 million$1.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALGSAligos TherapeuticsN/AN/AN/AN/AN/AASBPAspire BiopharmaN/AN/AN/AN/AN/AATHAAthira PharmaN/AN/AN/AN/AN/ADAREDare BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALGSAligos TherapeuticsN/A2.562.56ASBPAspire BiopharmaN/A2.262.14ATHAAthira PharmaN/A9.709.70DAREDare BioscienceN/A1.031.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALGSAligos Therapeutics60.43%ASBPAspire Biopharma19.17%ATHAAthira Pharma57.12%DAREDare Bioscience6.70%Insider OwnershipCompanyInsider OwnershipALGSAligos Therapeutics7.80%ASBPAspire Biopharma5.80%ATHAAthira Pharma19.80%DAREDare Bioscience4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALGSAligos Therapeutics906.19 million5.71 millionNo DataASBPAspire BiopharmaN/A1.30 million1.22 millionN/AATHAAthira Pharma403.94 million3.16 millionNo DataDAREDare Bioscience3014.98 million14.37 millionNot OptionableASBP, ALGS, DARE, and ATHA HeadlinesRecent News About These CompaniesDaré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” SegmentJune 25 at 9:05 AM | globenewswire.comDaré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026June 18, 2026 | globenewswire.comDaré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic CapsulesJune 4, 2026 | finance.yahoo.comDaré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel ...May 26, 2026 | caledonianrecord.comCDaré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of ...May 26, 2026 | finance.yahoo.comDaré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical CancerMay 26, 2026 | globenewswire.comDaré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved TherapiesMay 18, 2026 | globenewswire.comDaré Bioscience, Inc.: Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 15, 2026 | finanznachrichten.deDaré Bioscience targets Ovaprene Phase III to reach 2,500 exposure cycles in 2026 as Flora Sync LF5 revenue is expected to begin in JuneMay 15, 2026 | msn.comDare Bioscience Inc (DARE) Q1 2026 Earnings Call Highlights: Strategic Milestones and Financial ...May 15, 2026 | finance.yahoo.comDaré Bioscience, Inc. (DARE) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comDaré Bioscience Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 14, 2026 | globenewswire.comPositive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free ContraceptiveMay 12, 2026 | globenewswire.comDaré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026May 7, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE) and Iovance Biotherapeutics (IOVA)April 12, 2026 | theglobeandmail.comDaré’s CEO Wants Everyone To Invest in Women’s Health, Starting With Her CompanyApril 8, 2026 | biospace.comBDare Bioscience Inc.April 2, 2026 | barrons.comDaré Bioscience, Inc.: Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business UpdateMarch 27, 2026 | finanznachrichten.deDaré outlines 2026 revenue launch and multiplatform strategy as DARE to PLAY expands nationwideMarch 26, 2026 | seekingalpha.comDaré Bioscience, Inc. (DARE) Q4 2025 Earnings Call TranscriptMarch 26, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASBP, ALGS, DARE, and ATHA Company DescriptionsAligos Therapeutics NASDAQ:ALGS$5.59 +0.09 (+1.64%) As of 10:43 AM Eastern This is a fair market value price provided by Massive. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Aspire Biopharma NASDAQ:ASBP$6.36 -0.09 (-1.40%) As of 10:44 AM Eastern This is a fair market value price provided by Massive. Learn more.Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.Athira Pharma NASDAQ:ATHA$8.22 -0.39 (-4.53%) As of 06/5/2026Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Dare Bioscience NASDAQ:DARE$2.04 +0.04 (+2.00%) As of 10:44 AM Eastern This is a fair market value price provided by Massive. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Xcel Energy Stock Offers Stability as Electricity Demand Builds Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal MDA Space Targets US Defense Market With $620M Acquisition Qualcomm’s $4B AI Deal Takes Aim at NVIDIA’s Software Moat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
